Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici
Summary
The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.
What changed
This document is a published patent application from the USPTO for compounds identified as Janus Kinase (JAK) inhibitors. The application, filed by Chiesi Farmaceutici S.P.A., details compounds of general formula (I) and their potential therapeutic uses, particularly for inflammatory diseases such as asthma and COPD. The application includes specific CPC classifications related to heterocyclic derivatives and pharmaceutical compositions.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property rights for the assignee and may inform research and development strategies within the pharmaceutical sector. Companies operating in the organic chemistry and pharmaceutical manufacturing space should be aware of this filing for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
Application US20260085077A1 Kind: A1 Mar 26, 2026
Assignee
CHIESI FARMACEUTICI S.P.A.
Inventors
Alessandro ACCETTA, Alberto CUZZOLIN, Fabio RANCATI, Andrea RIZZI, Ivaylo Jivkov ELENKOV, Milan MESIC, Ela RADOŠEVIC
Abstract
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory diseases including asthma, COPD and other respiratory diseases.
CPC Classifications
C07D 519/00 A61K 9/007 A61K 31/519 A61K 31/5377 A61K 31/538 A61K 31/541 A61K 31/5415 A61K 31/553 A61K 45/06 C07D 471/04
Filing Date
2023-09-08
Application No.
19109331
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.